Aberdeen, United Kingdom

Edouard Monnais

This inventor holds 3 USPTO granted patents and 2 EPO patents. Top assignee: 4D Pharma Research Limited. Active years: 2017-2022.


% Patents Active = 66.7

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 62(Granted Patents)


Company Filing History:


Years Active: 2017-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Edouard Monnais: Innovator in Immune Modulation

Introduction

Edouard Monnais is a notable inventor based in Aberdeen, GB. He has made significant contributions to the field of immune modulation, holding a total of 3 patents. His work focuses on innovative solutions that address inflammation in tissues and organs.

Latest Patents

Monnais's latest patents include groundbreaking inventions related to polypeptides and immune modulation. One of his key inventions involves flagellin and/or a polynucleotide sequence encoding said flagellin. This invention also encompasses a vector comprising the polynucleotide sequence and a host cell, including bacteria, that comprises the vector. The primary application of this invention is to modulate inflammation in a tissue or organ in a subject.

Career Highlights

Edouard Monnais is currently associated with 4D Pharma Research Limited, where he continues to advance his research in immune modulation. His work has been instrumental in developing new therapeutic approaches that leverage the body's immune response.

Collaborations

Monnais collaborates with esteemed colleagues, including Angela Margaret Patterson and Denise Kelly. These partnerships enhance the innovative potential of his research and contribute to the advancement of the field.

Conclusion

Edouard Monnais stands out as a prominent inventor in the realm of immune modulation, with a focus on innovative solutions to inflammation. His contributions through patents and collaborations continue to shape the future of medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…